Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata
Sponsor: TetraLogic Pharmaceuticals
This PHASE2 trial investigates Alopecia Areata and is currently ongoing. TetraLogic Pharmaceuticals leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TetraLogic Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.